Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 28038


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28038

License Grant
The two pharmaceutical companies entered into a License and Commercialization Agreement that granted the exclusive right to commercialize licensor's pharmaceutical product Stendratm (avanafil) for the treatment of any urological disease or condition in humans, including male erectile dysfunction in the United States and Canada and their respective territories.
Field of Use
Avanafil (tradename: Stendra) is a phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).

IPSCIO Record ID: 245896

License Grant
Licensor grants an exclusive, even as to Licensor, sublicensable license under the Licensor Technology, to use, distribute, import, Promote, market, sell, offer for sale, and otherwise Commercialize Products in the Field in the Licensee Territory; and, make and have made Products in the Manufacturing Territory, where such Product is solely for use or sale in the Field in the Licensee Territory, and, to conduct certain Development activities on the Product in the Field solely in support of Regulatory Approval in the Licensee Territory; and, an exclusive, sublicensable license to use the Licensor Trademarks solely in connection with the
Commercialization of the Product in the Field in the Licensee Territory.
License Property
The Licensor has rights to a therapeutic drug known as STENDRA TM (avanafil).

Compound means the compound identified by the International NonProprietary Name avanafil and chemically known as (S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxyamide, including any metabolites, polymorphs, salts, esters, free acid forms, free base forms, pro-drug forms, racemates and all optically active forms thereof.

Product means pharmaceutical compositions containing the Compound, including but not limited to that drug product known as STENDRA â„¢, in the form, formulation, and dosage strength(s) as defined in the NDA approved by the FDA as of the Effective Date and any other improvements, line extensions, delivery mechanisms, dosage strengths, formulations, or forms as may be approved in the future by the FDA or Health Canada that, in each case, contain a Compound.

Licensor Trademarks means the mark STENDRA.

Field of Use
The Field means the treatment of any urological disease or condition in humans, including male erectile dysfunction.

STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.

IPSCIO Record ID: 4898

License Grant
The Company entered into a royalty agreement with the Licensor, an individual, for the intellectual rights to patent, develop, manufacture, and market the LLPGE-1 for the treatment of male erectile dysfunction, impotency and sexual enhancement.
License Property
U.S. Patent 573408: PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction.
Field of Use
The field of use relates to the medical industry.  The Licensee is a development stage biopharmaceutical company whose corporate objective is to utilize medically researched and developed drug substances for sexual dysfunction, determine the ability of these substances to be delivered effectively and determine the potential market for such products.

IPSCIO Record ID: 7215

License Grant
Licensor hereby grants a Korean  pharmaceutical company an exclusive royalty-bearing license, with the right to sublicense directly or through multiple tiers under the Licensor Technology, to research, Develop, Finish, use, have used, sell, have sold, offer for sale, have offered for sale, distribute, have distributed, import, have imported, and otherwise Commercialize the Products in the Field in the Territory.  For clarity, the foregoing licenses exclude the right to Manufacture or have Manufactured the Product, except for the right to Finish the Product.
License Property
The Licensee has made or will make certain specified milestone payments to the Licensor upon the signing of the Agreement, a specified period of time following approval of ZertaneTM for sale in South Korea, a specified period of time following approval of a combination drug for sale in South Korea and specified periods of time following the end of the first calendar quarter where cumulative net sales of products including ZertaneTM (including combination drugs) in South Korea exceed specified thresholds.
Field of Use
The Agreement provides the Licensee with exclusive rights to market ZertaneTM in South Korea for the treatment of premature ejaculation and for a combination drug, utilizing ZertaneTM and another erectile dysfunction drug (PDE5 inhibitors and others), to simultaneously treat premature ejaculation and erectile dysfunction.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.